Prevalence of Dementia amongst Elderly Japanese with Leprosy: Apparent Effect of Chronic Drug Therapy
The DOI matches its Crossref record.
Abstract
The overall prevalence of dementia in 1,410 Japanese leprosy patients 65 years or over continuously treated with dapsone or closely related drugs was 2.9%. This compares with 4.83% of 621 cases treated intermittently and 6.25 % of 1,761 cases untreated for at least 5 years. Multiple logistic regression analysis showed a highly significant increase of dementia with age (p = 0.0001) and, after age adjustment, a significant reduction of dementia in drug-treated compared with drug-free patients (p = 0.017). Such treatment had no significant effect on the prevalence of strokes. These data suggest that dapsone and closely related drugs may have potential use as antidementia agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Self-citationInflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
“1996) and leprosy (McGeer et al. 1992), in which chronic and substantial use of anti-inflammatory drugs would be expected.”
BackgroundSuh, Y.-H., & Checler, F. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.469 · Cited by 467
Inflammation and Alzheimer's disease pathogenesis
Rogers, J., Webster, S., Lue, L.-F., Brachova, L., Harold Civin, W., Emmerling, M., Shivers, B., Walker, D., & McGeer, P. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00115-7 · Cited by 442
Self-citationThe impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 397
THE ROLE OF ANTI-INFLAMMATORY DRUGS IN THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
Breitner, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.401 · Cited by 263
Local Neuroinflammation and the Progression of Alzheimer's Disease
McGeer, P. L., & McGeer, E. G. (2002) · Journal of Neurovirology · doi:10.1080/13550280290100969 · Cited by 255
Self-citationAlzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms
Halliday, G., Robinson, S. R., Shepherd, C., & Kril, J. (2000) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2000.03200.x · Cited by 208
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Bancher, C., Jellinger, K., Lassmann, H., Fischer, P., & Leblhuber, F. (1996) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02189115 · Cited by 130
Alzheimer’s disease as oligomeropathy
Ono, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.010 · Cited by 129
“Japan had a significantly lower incidence of dementia than that of an untreated group (McGeer et al., 1992).”
BackgroundWegiel, J., Wang, K. C., Tarnawski, M., & Lach, B. (2000) · Acta Neuropathologica · doi:10.1007/s004010000199 · Cited by 124
Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment
Imbimbo (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00019 · Cited by 75
Neuroimmune contributions to Alzheimer’s disease: a focus on human data
Haage, V., & De Jager, P. L. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01637-0 · Cited by 74
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
“Interest in the anti-leprosy antibiotic dapsone (4,4'-diaminodiphenylsulfone) as an AD therapy came from initial observations of lower incidence of AD in a population of Japanese leprosy patients, who had been treated for many years with this or similar anti-leprosy antibiotics [115].”
BackgroundAcuña, L., Hamadat, S., Corbalán, N. S., González-Lizárraga, F., dos-Santos-Pereira, M., Rocca, J., Sepúlveda Díaz, J., Del-Bel, E., Papy-García, D., Chehín, R. N., et al. (2019) · Cells · doi:10.3390/cells8080776 · Cited by 62
“In particular, leprosy patients subjected to a chronic treatment with Rif displayed a significantly decreased prevalence of dementia [15,16].”
BackgroundDiaminodiphenyl sulfone–induced parkin ameliorates age-dependent dopaminergic neuronal loss
Lee, Y.-I., Kang, H., Ha, Y. W., Chang, K.-Y., Cho, S.-C., Song, S. O., Kim, H., Jo, A., Khang, R., Choi, J.-Y., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.008 · Cited by 16
Metadata
- Authors
- McGeer, P. L., Harada, N., Kimura, H., McGeer, E. G., & Schulzer, M.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 1992
- Volume
- 3
- Issue
- 3
- Pages
- 146-149
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2047055473
- Cited by
- 103
- References
- 0
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.